At the University of Nebraska Medical Center (UNMC), a protocol was instituted in July 1985 for the use of OKT3 on a compassionate basis for patients who failed treatment of acute rejection with both steroids and Atgam. (ATG). This paper summarizes the results of our conventional immunosuppression with cyclosporine (Cs) and steroids, conventional therapy for acute rejection including steroids and ATG, and compassionate use of OKT3. We conclude that reserving OKT3 for use as the final-line therapy, after SR and Atgam have failed, yields results inferior to those obtained when OKT3 is used to treat steroid-resistant rejections. Our experience has shown, however, that most rejection episodes after OLT are readily reversed by using steroid therapy as outlined. From the data presented, OKT3 is at least as effective as Atgam in treating steroid-resistant rejections. In addition, OKT3 has the added advantage of being readily available and does not appear to be associated with a higher incidence of complications than does Atgam therapy.
|Original language||English (US)|
|Number of pages||6|
|Issue number||1 SUPPL. 1|
|State||Published - 1988|
ASJC Scopus subject areas